Webinar: Viltepso – A Treatment Option for Patients Amenable to Exon 53 Skipping (April 22, 2021)
by: Parent Project Muscular Dystrophy
NS Pharma joined PPMD for a webinar on April 22, 2021 to provide an update about VILTEPSO™, a treatment of Duchenne in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping, and its associated patient support program.
by: Parent Project Muscular Dystrophy
